Suppr超能文献

老年男性序贯使用抗病毒药物改善重症新型冠状病毒肺炎病情

Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs.

作者信息

Yatomi Masakiyo, Takazawa Tomonori, Yanagisawa Kunio, Kanamoto Masafumi, Matsui Yusuke, Tsukagoshi Hiroyuki, Saruki Nobuhiro, Saito Shigeru, Tokue Yutaka, Maeno Toshitaka

机构信息

Department of Allergy and Respiratory Medicine, Integrative Center of Internal Medicine, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, Japan 371-8511.

Intensive Care Unit, Gunma University Hospital, 3-39-15 Showa-machi, Maebashi, Gunma, Japan 371-8511.

出版信息

Case Rep Infect Dis. 2020 Sep 5;2020:8814249. doi: 10.1155/2020/8814249. eCollection 2020.

Abstract

Although a variety of existing drugs are being tested for patients with coronavirus disease 2019 (COVID-19), no efficacious treatment has been found so far, particularly for severe cases. We report successful recovery in an elderly patient with severe pneumonia requiring mechanical ventilation and extracorporeal membrane oxygenation (ECMO). Despite administration of multiple antiviral drugs, including lopinavir/ritonavir, chloroquine, and favipiravir, the patient's condition did not improve. However, after administration of another antiviral drug, remdesivir, we were able to terminate invasive interventions, including ECMO, and subsequently obtained negative polymerase chain reaction results. Although further validation is needed, remdesivir might be effective in treating COVID-19.

摘要

尽管目前正在对多种现有药物进行2019冠状病毒病(COVID-19)患者的试验,但迄今为止尚未发现有效的治疗方法,尤其是对重症病例。我们报告了一名患有严重肺炎、需要机械通气和体外膜肺氧合(ECMO)的老年患者成功康复的病例。尽管使用了多种抗病毒药物,包括洛匹那韦/利托那韦、氯喹和法匹拉韦,但患者的病情并未改善。然而,在使用另一种抗病毒药物瑞德西韦后,我们得以终止包括ECMO在内的侵入性干预措施,随后获得了聚合酶链反应阴性结果。尽管还需要进一步验证,但瑞德西韦可能对治疗COVID-19有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cbb/7475736/bdd52df41bce/CRIID2020-8814249.001.jpg

相似文献

1
Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs.
Case Rep Infect Dis. 2020 Sep 5;2020:8814249. doi: 10.1155/2020/8814249. eCollection 2020.
3
Successful recovery from critical COVID-19 pneumonia with extracorporeal membrane oxygenation: A case report.
Respir Med Case Rep. 2020 May 31;30:101113. doi: 10.1016/j.rmcr.2020.101113. eCollection 2020.
4
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.
Front Med (Lausanne). 2020 May 19;7:241. doi: 10.3389/fmed.2020.00241. eCollection 2020.
5
Extracorporeal Membrane Oxygenation Support in a Young Patient With COVID-19 Infection.
Cureus. 2020 Jun 19;12(6):e8694. doi: 10.7759/cureus.8694.
7
Severe adenovirus pneumonia requiring extracorporeal membrane oxygenation support--Serotype 7 revisited.
Respir Med. 2013 Nov;107(11):1810-3. doi: 10.1016/j.rmed.2013.09.008. Epub 2013 Sep 19.
8
Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn.
SAGE Open Med Case Rep. 2020 Oct 15;8:2050313X20964046. doi: 10.1177/2050313X20964046. eCollection 2020.
9
Severe Thrombocytopenia in a Patient with COVID-19.
Infect Chemother. 2020 Sep;52(3):410-414. doi: 10.3947/ic.2020.52.3.410. Epub 2020 Jul 13.
10
Pharmaceutical care of chloroquine phosphate in elderly patients with coronavirus pneumonia (COVID-19).
Aging Med (Milton). 2020 Apr 6;3(2):98-101. doi: 10.1002/agm2.12104. eCollection 2020 Jun.

引用本文的文献

1
The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection.
SAGE Open Med Case Rep. 2022 Jan 8;10:2050313X211066646. doi: 10.1177/2050313X211066646. eCollection 2022.

本文引用的文献

1
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
2
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
3
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Nat Rev Drug Discov. 2020 Mar;19(3):149-150. doi: 10.1038/d41573-020-00016-0.
4
Development of Genetic Diagnostic Methods for Detection for Novel Coronavirus 2019(nCoV-2019) in Japan.
Jpn J Infect Dis. 2020 Jul 22;73(4):304-307. doi: 10.7883/yoken.JJID.2020.061. Epub 2020 Feb 18.
5
Potential interventions for novel coronavirus in China: A systematic review.
J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
First Case of 2019 Novel Coronavirus in the United States.
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
9
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
10
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验